Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELDN Eledon Pharmaceuticals	$2.16 +6.9%	$1.79	$1.07 ▼ $2.95	$53.59M	0.87	88,598 shs	189,922 shs
LBPH Longboard Pharmaceuticals	$20.27 +8.6%	$20.11	$3.60 ▼ $28.15	$730.13M	1.24	1.30 million shs	503,726 shs
NBSE NeuBase Therapeutics	$0.42	$0.70	$0.39 ▼ $4.80	$1.58M	0.83	207,172 shs	58,425 shs
OCUP Ocuphire Pharma	$1.54 +2.0%	$2.14	$1.50 ▼ $6.60	$38.21M	0.34	220,937 shs	140,451 shs
ZSAN Zosano Pharma	$0.00	$3.90	$0.46 ▼ $37.45	$1K	3.3	425,375 shs	5,685 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELDN Eledon Pharmaceuticals	+8.60%	+23.17%	+0.50%	+18.82%	-23.77%
LBPH Longboard Pharmaceuticals	+7.05%	+2.30%	-6.56%	-28.36%	+157.52%
NBSE NeuBase Therapeutics	-4.42%	-1.49%	-60.10%	-32.99%	-86.54%
OCUP Ocuphire Pharma	-8.76%	-14.20%	-25.62%	-44.69%	-70.79%
ZSAN Zosano Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELDN Eledon Pharmaceuticals	2.3137 of 5 stars	3.5	3.0	0.0	0.0	1.1	1.7	1.3
LBPH Longboard Pharmaceuticals	1.5198 of 5 stars	3.5	1.0	0.0	0.0	2.6	2.5	0.0
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	1.756 of 5 stars	3.5	2.0	0.0	0.0	0.6	1.7	1.3
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELDN Eledon Pharmaceuticals	3.00	Buy	$10.67	393.83% Upside
LBPH Longboard Pharmaceuticals	3.00	Buy	$39.50	94.87% Upside
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	3.00	Buy	$19.00	1,133.77% Upside
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OCUP, LBPH, ELDN, NBSE, and ZSAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	LBPH Longboard Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
4/10/2024	LBPH Longboard Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$60.00
3/22/2024	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
3/20/2024	OCUP Ocuphire Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $20.00
3/15/2024	LBPH Longboard Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
3/13/2024	LBPH Longboard Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00
3/13/2024	LBPH Longboard Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$60.00
2/16/2024	LBPH Longboard Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
LBPH Longboard Pharmaceuticals	N/A	N/A	N/A	N/A	$1.67 per share	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OCUP Ocuphire Pharma	$19.05M	2.01	N/A	N/A	$2.20 per share	0.70
ZSAN Zosano Pharma	$790K	0.00	N/A	N/A	$9.74 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELDN Eledon Pharmaceuticals	-$40.33M	-$1.79	N/A	N/A	N/A	N/A	-46.15%	-43.10%	5/9/2024 (Estimated)
LBPH Longboard Pharmaceuticals	-$54.42M	-$2.38	N/A	N/A	N/A	N/A	-97.53%	-85.21%	5/14/2024 (Estimated)
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OCUP Ocuphire Pharma	-$9.99M	-$0.48	N/A	N/A	N/A	-52.42%	-22.30%	-20.27%	5/20/2024 (Estimated)
ZSAN Zosano Pharma	-$29.92M	-$14.50	N/A	∞	N/A	-8,375.11%	-177.06%	-119.14%	N/A

Latest OCUP, LBPH, ELDN, NBSE, and ZSAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/28/2024	Q4 2023	ELDN Eledon Pharmaceuticals	-$0.38	-$0.29	+$0.09	-$0.29	N/A	N/A
3/12/2024	Q4 2023	LBPH Longboard Pharmaceuticals	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
3/8/2024	Q4 2023	OCUP Ocuphire Pharma	-$0.07	-$0.21	-$0.14	-$0.21	$3.47 million	$1.69 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LBPH Longboard Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELDN Eledon Pharmaceuticals	N/A	14.41	14.41
LBPH Longboard Pharmaceuticals	N/A	5.14	5.14
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OCUP Ocuphire Pharma	N/A	13.35	13.35
ZSAN Zosano Pharma	N/A	1.61	1.61

Ownership

Institutional Ownership

Company	Institutional Ownership
ELDN Eledon Pharmaceuticals	56.77%
LBPH Longboard Pharmaceuticals	63.28%
NBSE NeuBase Therapeutics	12.37%
OCUP Ocuphire Pharma	14.97%
ZSAN Zosano Pharma	N/A

Insider Ownership

Company	Insider Ownership
ELDN Eledon Pharmaceuticals	19.40%
LBPH Longboard Pharmaceuticals	4.64%
NBSE NeuBase Therapeutics	13.90%
OCUP Ocuphire Pharma	8.70%
ZSAN Zosano Pharma	2.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ELDN Eledon Pharmaceuticals	17	24.81 million	20.00 million	Optionable
LBPH Longboard Pharmaceuticals	50	36.02 million	34.35 million	Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OCUP Ocuphire Pharma	14	24.81 million	22.65 million	Optionable
ZSAN Zosano Pharma	40	4.90 million	4.78 million	Not Optionable

OCUP, LBPH, ELDN, NBSE, and ZSAN Headlines

Source	Headline
	HOOK HOOKIPA Pharma Inc. seekingalpha.com - April 12 at 10:11 PM
	Nachrichten - Weitere Nachrichten wallstreet-online.de - January 9 at 2:39 PM
	LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan pbs.org - December 6 at 7:44 AM
	Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab n-tv.de - August 22 at 3:36 PM
	East Bay Business News bizjournals.com - May 18 at 9:49 PM
	Mankind Pharma IPO opens on April 25, listing scheduled for May 9 moneycontrol.com - April 27 at 4:20 PM
	Astellas Pharma forbes.com - April 6 at 12:00 PM
	Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation finance.yahoo.com - February 5 at 12:11 PM
	FTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders washingtonexaminer.com - January 23 at 3:25 PM
	Zosano Pharma Corporation (ZSANQ) ca.finance.yahoo.com - November 5 at 6:33 PM
	Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly endpts.com - October 13 at 11:22 AM
	Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants msn.com - October 12 at 2:32 PM
	Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims marketwatch.com - August 28 at 7:45 PM
	East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million bizjournals.com - August 27 at 4:10 PM
	Zosano Pharma Corp (ZSANQ) investing.com - August 25 at 12:28 AM
	East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M bizjournals.com - July 26 at 8:27 PM
	A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M. bizjournals.com - July 26 at 8:27 PM
	Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8 dbtnews.com - June 3 at 11:27 AM
	Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN marketwatch.com - June 2 at 3:26 PM
	Why Zosano Pharma Shares Are Getting Hammered Today msn.com - June 2 at 3:26 PM
	Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46% seekingalpha.com - June 2 at 10:26 AM
	Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN marketwatch.com - June 2 at 10:26 AM
	East Bay migraine patch developer files for bankruptcy bizjournals.com - June 2 at 10:26 AM
	Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Eledon Pharmaceuticals

NASDAQ:ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Longboard Pharmaceuticals

NASDAQ:LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Ocuphire Pharma

NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Zosano Pharma

NASDAQ:ZSAN

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial